Welcome to our dedicated page for Geron SEC filings (Ticker: GERNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Geron's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Geron's regulatory disclosures and financial reporting.
Geron Corp reported that EVP and Chief Legal Officer Timothy Williams received a grant of stock options. He was awarded options to buy 2,500,000 shares of Geron common stock at an exercise price of $1.73 per share, expiring on April 12, 2036.
According to the vesting terms, 312,500 shares underlying the option will vest on October 13, 2026, with the remaining shares vesting in equal installments over the following 42 months, assuming he continues serving the company on each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
GERON CORP executive Timothy Williams, EVP and Chief Legal Officer, has filed an initial Form 3 as a reporting person. The available data show no reported transactions or holdings, reflecting a baseline regulatory ownership filing rather than any new buying or selling activity.
Geron Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on May 20, 2026 at 2:00 p.m. Eastern. Holders of 640,900,330 common shares as of March 26, 2026 may vote.
Proposals include electing three Class III directors, adding 4,500,000 shares to the 2018 Equity Incentive Plan, an advisory vote on executive pay, and ratifying Ernst & Young LLP as auditor for 2026. The meeting will be held online at www.virtualshareholdermeeting.com/GERN2026, where investors can attend, submit questions, and vote using their 16-digit control number.
Spiegel Robert J. reported acquisition or exercise transactions in this Form 4 filing.
Geron Corp director Robert J. Spiegel received 5,243 shares of common stock as part of his board compensation. The shares were granted in lieu of cash for his quarterly board retainer and committee fees, using a reference price of $1.49 per share based on the March 31, 2026 closing price. Following this stock award, he directly holds 199,707 Geron common shares.
The Vanguard Group filed an Amendment No. 1 to a Schedule 13G/A stating it beneficially owns 0 shares of Geron Corp, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries/divisions to report separately. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Geron Corp director Constantine Chinoporos received a grant of stock options, not an open-market share purchase. The award covers 270,000 options to buy Geron common stock at an exercise price of $1.57 per share and expires on March 24, 2036.
The options will vest in three equal annual installments starting on March 25, 2027, subject to his continuous service with the company through each vesting date. Following this grant, he holds 270,000 stock options directly according to the filing.
Geron Corp director files initial ownership report with no trades
Geron Corp director Constantine Chinoporos has filed an initial ownership statement as a company insider. This Form 3 filing establishes his status as a director of Geron Corp but does not report any stock transactions or derivative positions.
Geron Corporation director Patricia S. Andrews received a grant of 270,000 stock options to buy Geron common stock. The options have an exercise price of $1.57 per share and expire on March 24, 2036. They vest in three equal annual installments starting on March 25, 2027, contingent on her continued service. Following this grant, she holds 270,000 stock options directly.
Geron Corp director Patricia S. Andrews has filed an initial insider ownership report with the SEC. This Form 3 filing establishes her status as a director of Geron Corp (ticker GERN) and provides a baseline disclosure of her holdings, with no transactions reported in this filing.
Geron Corporation is registering up to $150,000,000 of common stock for resale under an at-the-market sales agreement with TD Securities (USA) LLC (TD Cowen) dated February 27, 2026, to be sold from time to time through or to TD Cowen as sales agent or principal.
The prospectus is a shelf registration on Form S-3 that also permits future offerings of preferred stock, debt securities and warrants; the Sales Agreement tranche specifically covers common stock with compensation to TD Cowen up to 3.0% of gross proceeds and customary indemnities. Sales may be made by negotiated transactions, block trades or through trading markets.